gilbert.eu

What It Is

Gilbert B.V. is a respiratory medical device company based at the High Tech Campus in Eindhoven, the Netherlands, and originated from Delft University of Technology. It is not a traditional SaaS or enterprise software company. Instead, it develops next-generation Smart Precision Inhaler soft-mist inhalers based on proprietary Electrospray / electrohydrodynamic atomization (EHDA) technology, designed for precise pulmonary drug delivery in difficult-to-treat lung diseases.

Core Capabilities

According to the website, Gilbert’s core capability lies in customizable aerosol generation: using an electric field to atomize liquids into a monodisperse soft mist with adjustable particle sizes, with the potential to deliver drugs more precisely to targeted regions of the lungs. The device design includes breath-triggered dosing to reduce the need for patient inhalation coordination and minimize drug waste. The soft-mist inhalation experience may help make the device easier to use. Its smart module includes automatic monitoring, feedback, reminders, dose tracking, and a mobile app to improve adherence and care coordination.

Pricing and Business Model

The website does not disclose standard pricing, subscription plans, free trials, or payment methods. Its business model is closer to that of a medical device and drug delivery platform partnership: Gilbert works with pharmaceutical, biotechnology, and academic institutions, helping optimize aerosolization and pulmonary delivery of inhaled drug formulations from early feasibility studies through the clinical trial stage.

Pros and Cons

Its strengths lie in its clearly differentiated technical approach. EHDA can generate monodisperse, adjustable droplets, offering potential compatibility with high-value sensitive compounds, biologics, and small-molecule drugs. The company already has a handheld functional prototype, a patent portfolio, and partnerships with organizations such as TU Delft and Philips Engineering Solutions. The limitations are that the product is still in the development and feasibility study stage, with no visible evidence of market launch, regulatory approval, mass production, or real-world clinical outcome data. It also lacks the API, permissions, third-party software integrations, and data security disclosures commonly seen in SaaS products.

Who It’s For and Access in China

Gilbert is better suited for pharmaceutical companies, biotechnology firms, and respiratory disease research institutions evaluating next-generation inhaled drug delivery solutions, especially for unmet-need scenarios such as cystic fibrosis and severe asthma. The text does not disclose information on access from China or local registration/sales status, so this remains unknown.